Biologics in myelodysplastic syndrome-related systemic inflammatory and autoimmune diseases: French multicenter retrospective study of 29 patients.

[1]  C. Cazalets,et al.  Intravenous immunoglobulins in systemic sclerosis: Data from a French nationwide cohort of 46 patients and review of the literature. , 2017, Autoimmunity reviews.

[2]  G. Mufti,et al.  Autoimmune diseases and myelodysplastic syndromes , 2016, American journal of hematology.

[3]  O. Decaux,et al.  Efficacy of Azacitidine in Autoimmune and Inflammatory Disorders associated with Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia Running title : Azacitidine in autoimmune disorders associated with MDS / CMML , 2018 .

[4]  J. Piette,et al.  Systemic inflammatory and autoimmune manifestations associated with myelodysplastic syndromes and chronic myelomonocytic leukaemia: a French multicentre retrospective study. , 2016, Rheumatology.

[5]  C. Salvarani,et al.  Biologics in vasculitides: Where do we stand, where do we go from now? , 2015, Presse medicale.

[6]  Pierre Fenaux,et al.  Inflammatory Arthritis in Patients With Myelodysplastic Syndromes , 2014, Medicine.

[7]  J. Maciejewski,et al.  Epidemiology and risk factors for infections in myelodysplastic syndromes , 2013, Transplant infectious disease : an official journal of the Transplantation Society.

[8]  T. Chiba,et al.  Refractoriness of Intestinal Behçet's Disease with Myelodysplastic Syndrome Involving Trisomy 8 to Medical Therapies - Our Case Experience and Review of the Literature , 2013, Digestion.

[9]  S. Sait,et al.  Myelodysplastic syndromes and autoimmune diseases--case series and review of literature. , 2013, Leukemia research.

[10]  F. Baron,et al.  Value of infliximab (Remicade®) in patients with low-risk myelodysplastic syndrome: final results of a randomized phase II trial (EORTC trial 06023) of the EORTC Leukemia Group , 2012, Haematologica.

[11]  D. Henrion,et al.  Systemic and immune manifestations in myelodysplasia: A multicenter retrospective study , 2011, Arthritis care & research.

[12]  P. Wallace,et al.  Treating myelodysplastic syndrome improves an accompanying autoimmune disease along with a reduction in regulatory T-cells. , 2011, Leukemia research.

[13]  C. Salvarani,et al.  A case of arthritis and vasculitis associated with the refractory anemia with excess of blasts syndrome resistant to glucocorticoid treatment that responded favorably to TNF-alpha blockade. , 2006, Clinical and experimental rheumatology.

[14]  S. Amadori,et al.  Infliximab chimeric antitumor necrosis factor-α monoclonal antibody as potential treatment for myelodysplastic syndromes , 2005, Leukemia & lymphoma.

[15]  H. Deeg,et al.  Soluble TNF receptor fusion protein (etanercept) for the treatment of myelodysplastic syndrome: A pilot study , 2002, Leukemia.

[16]  J. Kuroda,et al.  Trisomy 8 Involved in Myelodysplastic Syndromes as a Risk Factor for Intestinal Ulcers and Thrombosis — Behçet's Syndrome , 2001, Leukemia & lymphoma.

[17]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[18]  W. Miller,et al.  Autoimmune phenomena in patients with myelodysplastic syndromes. , 1997, Leukemia & lymphoma.

[19]  G. Vercellotti,et al.  Paraneoplastic autoimmune phenomena in patients with myelodysplastic syndromes: response to immunosuppressive therapy , 1995, British journal of haematology.